Current Topics in Marmoset Anesthesia and Analgesia

Goodroe, Anna; Fitz, Casey; Bakker, Jaco

doi:10.1093/ilar/ilab001

Cited by 12 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, no abnormal behaviors or clinical signs, or injection site reactions were observed. By comparison, PK studies in the common marmoset 10,11 using a polymer‐based compounded long‐acting SR‐BUP demonstrated mild localized erythema and swelling of tissues around the injection site, which was reversible over time. This was not observed with Ethiqa XR in marmosets 12 .…”

Section: Discussionmentioning

confidence: 99%

A pharmacokinetic study of extended‐release buprenorphine in cynomolgus monkeys (Macaca fasicularis)

Klein¹,

Levinson²,

Leary³

et al. 2023

J of Medical Primatology

View full text Add to dashboard Cite

BackgroundA novel buprenorphine (BUP) extended‐release formulation (BUP‐XR) produced as a lipid‐encapsulated, low viscosity BUP suspension for subcutaneous (SC) injection to control pain was evaluated for pharmacokinetics and safety in four adult male cynomolgus monkeys.MethodsEach animal was given 0.2 mg/kg reformulated BUP‐XR SC. Clinical observations were made during the course of the study. Blood samples were obtained from each animal before BUP‐XR administration, 6, 24, 48, 72, and 96 h post‐BUP‐XR injection. Plasma levels of buprenorphine were analyzed using HPLC‐MS/MS. The PK values calculated included peak plasma concentration of the BUP analyte, time to peak plasma concentration, plasma half‐life, area under the plasma concentration–time curve, clearance, apparent volume of distribution, and elimination rate constant (Cmax, Tmax, T½, AUC0‐t, CL, Vd, and Ke, respectively).ResultsObservable adverse clinical signs were not detected. BUP concentration peaked from 6 to 48 h, then declined in a linear fashion. Quantifiable plasma BUP was measured in all monkeys at all time points. Results indicate that a single BUP‐XR dose at 0.2 mg/kg can reliably provide plasma levels of BUP reported in the literature to be therapeutically relevant for up to 96 h.ConclusionsBecause of the lack of any clinical observations or adverse effects at the injection site or absence of observable abnormal behaviors, it may be concluded that the use of BUP‐XR is safe and efficacious in this species of non‐human primate at the dose regimen described in this study for up to 96 h post‐administration.

show abstract

Section: Discussionmentioning

confidence: 99%

A pharmacokinetic study of extended‐release buprenorphine in cynomolgus monkeys (Macaca fasicularis)

Klein¹,

Levinson²,

Leary³

et al. 2023

J of Medical Primatology

View full text Add to dashboard Cite

show abstract

“…Anesthetic and analgesic protocols should be optimized for specific animal species and experimental purposes. Diverse anesthetic and analgesic regimes for marmosets have been reviewed recently [45,46]; in this section, we describe our procedures and some cautionary notes based on our experience at CIEA. Table 2 lists the anesthetic protocols, including premedication, emergency drugs, and postoperative analgesic doses for marmosets currently in use at CIEA.…”

Section: Anesthesia and Analgesia Protocols In Marmosetsmentioning

confidence: 99%

“…BSM-3592, Nihon Kohden) are used. Other sensors of SpO2 designed for pediatric use or rodents are available for marmosets [46]. During a major surgery or long anesthesia, in addition to respiration, SpO2, and pulse, rectal temperature and electrocardiogram are monitored.…”

Section: Anesthesia and Analgesia Protocols In Marmosetsmentioning

confidence: 99%

The common marmoset in biomedical research: experimental disease models and veterinary management

et al. 2023

View full text Add to dashboard Cite

The common marmoset, Callithrix jacchus, is increasingly being used as the preferred nonhuman primate (NHP) model in biomedical research. Marmosets share several physiological and biological similarities with humans, as a Simiiformes species, and their use in research programs advances knowledge of several fields. Their unique characteristics, such as small size, high fecundity, and rapid growth, offer additional advances in laboratory settings. This article reviews the developments in experimental disease models using marmosets based on our experience at the Central Institute for Experimental Animals (CIEA) in Japan. The development of genetically modified marmoset models using advanced genome editing technology attracts researchers, particularly in neuroscience-related fields. In parallel, various marmoset models of human diseases induced by surgery or drug administration have contributed to preclinical and translational studies. Among these are models for Parkinson's disease, induced by 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine; spinal cord injury models; a model for type 1 diabetes, induced by the combination of partial pancreatectomy and streptozotocin administration; and a hepatic fibrosis model induced by thioacetamides. The development of these models has been supported by refinements in veterinary care, such as the careful design of anesthetic protocols and better understanding of pathogenic microorganisms. In the second part of this review, we present a compilation of practices currently in use at CIEA that provide optimal animal care and enable safe experimentation.

show abstract

“…The safe use of Telazol ® has already been documented in nonhuman primates including capuchin monkeys [ 11 , 12 ], owl monkeys [ 13 ], rhesus macaques [ 14 , 15 , 16 ], cynomolgus macaques [ 17 ], baboons [ 14 ], chimpanzees [ 18 , 19 , 20 ], and southern brown howler monkeys [ 21 ]. There are a few reports of Telazol ® administration to marmosets, showing a wide dose range [ 9 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. However, evidence-based sedation and anesthetic dose determination for marmosets have never been performed.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Anesthetic and Cardiorespiratory Effects after Intramuscular Administration of Three Different Doses of Telazol® in Common Marmosets (Callithrix jacchus)

Goodroe

Bakker

Remarque

et al. 2023

Veterinary Sciences

Self Cite

View full text Add to dashboard Cite

Marmosets’ small body size makes anesthesia challenging. Ideally, small volumes of drugs should be administered intramuscularly (i.m.). In addition, dose-dependent sedation and anesthesia are desirable properties for sedatives and anesthetics in marmosets. Telazol (tiletamine and zolazepam) is highly concentrated, allowing the use of small injection volumes and dose-dependent sedation and anesthesia. A randomized, blinded study with crossover design in ten healthy adult common marmosets (Callithrix jacchus) was performed to evaluate the anesthetic and cardiorespiratory effects of three doses of i.m. Telazol (respectively, 5, 10, and 15 mg/kg). Depth of anesthesia, cardiorespiratory effects, and induction, immobilization, and recovery times were determined. There was a significant difference in immobilization time between 5 and 15 mg/kg of Telazol. In addition, 15 mg/kg of Telazol resulted in increased recovery times compared to 5 mg/kg. The cardiorespiratory effects during the first 45 min of immobilization were within clinically acceptable limits. The pedal withdrawal reflex was the best indicator of the anesthetic depth.

show abstract

Current Topics in Marmoset Anesthesia and Analgesia

Cited by 12 publications

References 49 publications

A pharmacokinetic study of extended‐release buprenorphine in cynomolgus monkeys (Macaca fasicularis)

A pharmacokinetic study of extended‐release buprenorphine in cynomolgus monkeys (Macaca fasicularis)

The common marmoset in biomedical research: experimental disease models and veterinary management

Evaluation of Anesthetic and Cardiorespiratory Effects after Intramuscular Administration of Three Different Doses of Telazol® in Common Marmosets (Callithrix jacchus)

Contact Info

Product

Resources

About